Breast Cancer

Although CDK4/6 inhibitors prolong progression-free survival for patients with estrogen receptor-positive breast cancer, the ideal treatment for each patient is currently unclear until adverse effects appear.

The research presented at the 2019 San Antonio Breast Cancer Symposium suggests that the different mechanisms could be exploited to overcome CDK4/6 inhibitor resistance in breast cancer patients.

Check the Pharmacy Times® website for more information and be sure to watch for daily newsletters, online conference articles and videos, and social media updates.

Men with breast cancer had higher mortality than women regardless of cancer type, treatment, and access to care.

Specialty Pharmacy Times will be on-site in San Antonio, TX, for the 2019 San Antonio Breast Cancer Symposium, taking place December 10 to 14, 2019.

Trastuzumab-dkst (Ogivri, Mylan, Biocon), a biosimilar to trastuzumab (Herceptin, Genentech Inc.), has been launched in the US, according to an announcement from Mylan N.V. and Biocon Ltd. It is the first biosimilar approved by the FDA and recommended by the FDA Oncologic Drugs Advisory Committee.

Weight loss surgery found to cut the overall risk of developing cancers linked to obesity by 20%.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The black-white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades.

Fulvestrant injection treats certain types of breast cancer in post-menopausal women who were not previously treated with endocrine therapy and as a combination for advanced or metastatic breast cancer.

Cyclin-Dependent Kinase 4/6 Inhibitors, Margetuximab, Trastuzumab Deruxtecan, and Tyrosine Kinase Inhibitors Have Shown Promising Results

Older women with breast cancer who have a concurrent mental health condition are more likely to use opioids and have worse survival outcomes.

The newly approved therapy is equivalent to AstraZeneca Pharmaceuticals’ Faslodex injection, 250mg/5mL.

Researchers achieve first success in linking a solid tumor with blood biomarkers, which is often an indicator of whether a patient with breast cancer will remain in remission.

In addition to a natural variation in genetic makeup, approximately 1 in 1000 people inherit a damaged or mutated copy of the BRCA1 gene from a parent.

Study finds elevated risk factors for cardiovascular disease in postmenopausal women with a history of breast cancer.

Study findings suggest that triple-negative breast cancer incidence among black women is not generalizable to all women of African descent.

Officials with the FDA approved Amgen’s trastuzumab-anns, also known as ABP 980 (Kanjinti), the fifth FDA-approved biosimilar referencing trastuzumab (Herceptin).

An unhealthy microbiome caused by chronic antibiotic treatment could result in long-term inflammation within the tissue and tumor environment.

Breast cancers with somatic or germline BRCA 1/2 mutations may not be as responsive to checkpoint inhibitors as previously thought.

A study investigates whether a high-dose of vitamin D with or without exercise is a safe, effective option to prevent bone loss.

Daily servings of fruits, vegetables, and grains associated with a lower risk of death from breast cancer.

An abstract presented at the 2019 American Society of Clinical Oncology Annual Meeting showed end-of-study analysis results of the phase 3 CLEOPATRA trial.

Genomic data may improve the selection of more precise models for metastatic breast cancer research.

Study suggests future interventions targeting improvements in cancer screenings may need to focus on the time of day when a patient visits a doctor.

Using genetic testing for women newly diagnosed with breast cancer can decrease the high cost of chemotherapy use in the first year of care.

The combination of selinexor and 4-OHT may be able to prevent endocrine resistance in hormone-responsive breast cancer by rewiring gene pathways.

Top news of the day from across the health care landscape.

The indication’s expansion for palbociclib to include male patients is based upon data from postmarketing reports and electronic health records showing that the safety profile for men treated with the drug is consistent with the safety profile in women treated with this medication.